Good news! We seem to be a few steps closer to finally getting a vaccine. After months of trial and error, the vaccine has been improved and could be making its way to us soon.
The vaccine, developed by Pfizer and BioNTech SE can prevent 90% of Covid-19 infections.
These findings come after Pfizer and BioNTech conducted a study involving 43,538 participants. A total of 94 participants had confirmed cases of Covid-19.
The trial will continue until 164 confirmed cases have been reached in order to collect more data and understand the virus.
According to Pfizer, the vaccine is most effective when taken in 2 doses.
"This means that protection is achieved 28 days after the initiation of the vaccination, which consists of a 2-dose schedule. As the study continues, the final vaccine efficacy percentage may vary." said Pfizer in a statement.
Phase 3 of the trial began on 27 July with approximately 40% of the participants coming from diverse racial and ethnic backgrounds.
By November 8, Pfizer had recorded a total of 38,955 participants who have received a second vaccine during the trial.
As the trial continues to take place, the study will try to uncover how effective the vaccine is in preventing infections in those who have previously had Covid-19 as well as those with severe cases.
“We are reaching this critical milestone in our vaccine development program at a time when the world needs it most with infection rates setting new records, hospitals nearing over-capacity and economies struggling to reopen. With today’s news, we are a significant step closer to providing people around the world with a much-needed breakthrough to help bring an end to this global health crisis." said Dr. Albert Bourla, Pfizer Chairman and CEO.
Pfizer and BioNTech will continue to collect safety data over the next two months. Participants who have taken part in the study will continue to be monitored and receive long-term protection two years after their second dose.
An estimated 50 million vaccine doses are expected to be produced by the end of this year and up to 1.3 billion doses in the year 2021.